Roche’s pricey new hemophilia drug Hemlibra gets a rare blessing from U.S. cost watchdogs

As the hemophilia market gets increasingly crowded, Roche needs all the help it can get generating enthusiasm for its new entry, Hemlibra. A thumbs-up from the cost watchdogs at the Institute for Clinical and Economic Review (ICER)—who decided Hemlibra is cost-effective, despite its north-of-$400K price—could do just that.Original Article